Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Assets: 2022-2025

Historic Assets for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $360.3 million.

  • Stoke Therapeutics' Assets rose 22.82% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.3 million, marking a year-over-year increase of 22.82%. This contributed to the annual value of $271.6 million for FY2024, which is 18.92% up from last year.
  • Per Stoke Therapeutics' latest filing, its Assets stood at $360.3 million for Q3 2025, which was down 6.31% from $384.5 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Assets high stood at $406.9 million for Q1 2025, and its period low was $205.2 million during Q1 2024.
  • Moreover, its 3-year median value for Assets was $281.8 million (2023), whereas its average is $294.2 million.
  • Per our database at Business Quant, Stoke Therapeutics' Assets declined by 27.19% in 2024 and then soared by 98.31% in 2025.
  • Stoke Therapeutics' Assets (Quarterly) stood at $256.1 million in 2022, then dropped by 10.83% to $228.3 million in 2023, then climbed by 18.92% to $271.6 million in 2024, then increased by 22.82% to $360.3 million in 2025.
  • Its last three reported values are $360.3 million in Q3 2025, $384.5 million for Q2 2025, and $406.9 million during Q1 2025.